Sometimes a single patient can change everything. REGENXBIO Inc. (RGNX) learned that lesson the hard way on Wednesday, watching its shares crater over 20% after the FDA threw up stop signs on two of its gene therapy programs. Trading volume exploded to 3.83 million shares—more than five times the typical 684,271 daily average—as investors digested news that nobody wanted to hear.

The trigger? One patient treated with the company's experimental gene therapy developed a neoplasm, which is medical-speak for abnormal tissue growth. And while neoplasms aren't always cancer, they're especially concerning when they show up in cutting-edge gene therapies designed to treat children with devastating genetic disorders.

When One Program Gets Held, Sometimes Two Do

The FDA's clinical hold affects both RGX-111 and RGX-121, REGENXBIO's investigational treatments for rare metabolic diseases. The neoplasm case emerged in someone treated with RGX-111, which targets MPS I—better known as Hurler syndrome. Kids born with this inherited condition lack a crucial enzyme needed to digest sugar, causing unprocessed sugar molecules to accumulate throughout the body.

But here's where things get complicated: the FDA also halted RGX-121, which treats a different but related disorder called MPS II or Hunter syndrome. Same basic problem—children lack the enzyme iduronate 2-sulfatase, leading to sugar buildup—but technically a separate condition. The agency's reasoning? The products are similar enough, the patient populations overlap, and the risks appear shared between the two trials.

REGENXBIO was quick to note that no other participants treated with either RGX-111 or RGX-121 have shown evidence of neoplasms. The company's CEO expressed surprise at the FDA's decision to hold RGX-121, pointing to what he described as a favorable safety profile backed by data from more than 30 patients, some treated nearly seven years ago.

Technical Damage Piles Up

The regulatory news sent the stock into freefall, and the technical picture looks bruised. Shares are now trading 23.4% below their 20-day simple moving average and 9.9% beneath the 100-day SMA—classic signs of short-term distress. Over the past year, the stock had actually climbed 44.41%, but Wednesday's selloff pushed it much closer to 52-week lows than highs.

The momentum indicators tell a murky story. The RSI sits at 45.56, which is neutral territory—not oversold, not overbought, just kind of stuck. Meanwhile, the MACD has dropped below its signal line, flashing bearish warnings. Together, they suggest mixed momentum and a stock searching for direction.

• Key Resistance: $12.00
• Key Support: $11.00

Analysts Still Believers Despite the Setback

Wall Street hasn't abandoned ship just yet. The stock carries a Buy rating with an average price target of $31.38—nearly triple where it's currently trading. Recent analyst activity shows continued confidence:

• Stifel: Buy rating with a target raised to $45.00
• Leerink Partners: Outperform rating with a target raised to $20.00
• Chardan Capital: Buy rating maintaining a $52.00 target

Investors will get their next major data point on March 12, 2026, when the company reports earnings. Analysts are expecting an 86-cent loss per share, which would actually represent improvement from the $1.01 loss in the year-ago period. Revenue estimates call for $50.09 million, more than doubling from $21.21 million a year earlier.

Momentum Score Says One Thing, Price Action Says Another

Here's an interesting wrinkle: despite the regulatory drama and Wednesday's selloff, REGENXBIO scores an impressive 91.62 on momentum metrics, suggesting the stock has been outperforming the broader market. That strength indicator feels awfully disconnected from a 20% down day, but it reflects longer-term performance trends rather than single-session moves.

The bottom line for investors is straightforward but uncomfortable: REGENXBIO faces meaningful regulatory uncertainty that won't resolve quickly. Clinical holds can last weeks or months depending on what the FDA needs to see. The company will need to address safety concerns convincingly enough to get both programs back on track, all while reassuring investors that its gene therapy platform remains viable for treating ultra-rare diseases.

RGNX Price Action: REGENXBIO shares were down 20.21% at $10.70 at the time of publication on Wednesday.